1st Bioprocessing and Manufacturing of Gene and Cell Therapy Products Course
October 4th – 8th, 2020
Gene and cell products are paving the way towards more effective therapeutics for unmet medical needs. Currently, one of the main translational challenges is a consistent and cost-effective supply of these complex medicinal products.
Taking into account the interest raised by ESACT members and other learned societies, we are organizing the 1st Bioprocessing and Manufacturing of Gene and Cell Therapy Products Course in Llafranc, Costa Brava/Spain, in October 2020. ESACT is introducing this activity as one more contribution to the community targeting the use of viral vectors, stem cells and immune cells for therapy.
This inaugural course is intended for Ph.D. students, post-docs, junior scientists, engineers and clinicians searching to improve their understanding of the development and manufacturing of gene and cell therapy products. The speakers will address key bioprocessing aspects, analytical toolsets to assess the quantity and quality attributes, and regulatory challenges for the manufacturing of ATMPs, providing also a solid fundamental basis on vectorology and stem cell biology.
The course is designed as an interactive 4-day program with the number of participants restricted to 30 to foster interaction among speakers and attendees.
A limited number of grants, covering the course fee (not travel costs), will be provided by ESACT. Applicants should state it in the course application, and provide a motivation statement. Priority for grants will be given to Ph.D. students and Post-Docs from academia.
Eric J Kremer
Institut de Génétique Moléculaire de Montpellier, France
Servei Terapia Cellular at Banc de Sang I Teixits
Edifici Dr. Frederic Duran i Jordà Passeig Taulat
116 08005 Barcelona, Spain
Paula Alves, iBET, Portugal
Animal Cell Technology Unit
Apartado 12, 2780-901 Oeiras, Portugal
Contact for registration